Reuters reports that Johnson & Johnson (JNJ +1%) has withdrawn from the list of potential suitors for Pfizer's (PFE +0.3%) consumer health business, leaving GlaxoSmithKline (GSK) and Reckitt Benckiser (OTCPK:RBGPF)(OTCPK:RBGLY) among those preparing bids, due by February 1.
According to sources close to the matter, Pfizer expects to sell the business for no less than $20B or 20x earnings. It generated $3.4B in sales in 2016.
READ FULL ARTICLE HERE

